



## **Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference**

May 12, 2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference and will present a company overview at 3:30 p.m. ET on May 19, 2026.

A live webcast of the presentation will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at <http://www.serestherapeutics.com> and will be available for replay following the event.

### **About Seres Therapeutics**

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics, with a focus on inflammatory and immune diseases. The Company led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, which has received Breakthrough Therapy and Fast Track designations, is being advanced for patients undergoing allogeneic hematopoietic stem cell transplant, and is Phase 2 ready, pending receipt of funding. An investigator-sponsored trial of SER-155 is ongoing in immune checkpoint inhibitor–related enterocolitis to further evaluate the potential breadth of the Company's live biotherapeutic platform. SER-603, in development for inflammatory bowel disease, is designed to modulate the gastrointestinal microbiome and support mucosal barrier integrity by targeting inflammatory bacteria and associated metabolites. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

### **Investor and Media Contact:**

[IR@serestherapeutics.com](mailto:IR@serestherapeutics.com)

Carlo Tanzi, Ph.D.

Kendall Investor Relations

[ctanzi@kendallir.com](mailto:ctanzi@kendallir.com)



Source: Seres Therapeutics, Inc.